Tags

Type your tag names separated by a space and hit enter

Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.

Abstract

OBJECTIVES

The post-hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS-cog single-items or SIB subscales for patients with moderate to severe AD.

METHODS

Data from six multicentre, randomised, placebo-controlled, parallel-group, double-blind, 6-month studies were used as the basis for these post-hoc analyses. All patients with a Mini-Mental State Examination (MMSE) score of less than 20 were included. Analyses of patients with moderate AD (MMSE: 10-19), evaluated with the Alzheimer's disease Assessment Scale (ADAS-cog) and analyses of patients with moderate to severe AD (MMSE: 3-14), evaluated using the Severe Impairment Battery (SIB), were performed separately.

RESULTS

The mean change from baseline showed a significant benefit of memantine treatment on both the ADAS-cog (p < 0.01) and the SIB (p < 0.001) total score at study end. The ADAS-cog single-item analyses showed significant benefits of memantine treatment, compared to placebo, for mean change from baseline for commands (p < 0.001), ideational praxis (p < 0.05), orientation (p < 0.01), comprehension (p < 0.05), and remembering test instructions (p < 0.05) for observed cases (OC). The SIB subscale analyses showed significant benefits of memantine, compared to placebo, for mean change from baseline for language (p < 0.05), memory (p < 0.05), orientation (p < 0.01), praxis (p < 0.001), and visuospatial ability (p < 0.01) for OC.

CONCLUSION

Memantine shows significant benefits on overall cognitive abilities as well as on specific key cognitive domains for patients with moderate to severe AD.

Links

  • Publisher Full Text
  • Authors+Show Affiliations

    ,

    Institute of Gerontology and Geriatrics, University of Perugia, Perugia, Italy. mecocci@unipg.it

    ,

    Source

    MeSH

    Activities of Daily Living
    Aged
    Alzheimer Disease
    Cognition
    Data Interpretation, Statistical
    Disease Progression
    Double-Blind Method
    Excitatory Amino Acid Antagonists
    Female
    Humans
    Language Disorders
    Male
    Memantine
    Memory
    Multicenter Studies as Topic
    Neuropsychological Tests
    Placebos
    Randomized Controlled Trials as Topic
    Severity of Illness Index
    Treatment Outcome

    Pub Type(s)

    Journal Article
    Research Support, Non-U.S. Gov't

    Language

    eng

    PubMed ID

    19274640

    Citation

    Mecocci, Patrizia, et al. "Effects of Memantine On Cognition in Patients With Moderate to Severe Alzheimer's Disease: Post-hoc Analyses of ADAS-cog and SIB Total and Single-item Scores From Six Randomized, Double-blind, Placebo-controlled Studies." International Journal of Geriatric Psychiatry, vol. 24, no. 5, 2009, pp. 532-8.
    Mecocci P, Bladström A, Stender K. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. Int J Geriatr Psychiatry. 2009;24(5):532-8.
    Mecocci, P., Bladström, A., & Stender, K. (2009). Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. International Journal of Geriatric Psychiatry, 24(5), pp. 532-8. doi:10.1002/gps.2226.
    Mecocci P, Bladström A, Stender K. Effects of Memantine On Cognition in Patients With Moderate to Severe Alzheimer's Disease: Post-hoc Analyses of ADAS-cog and SIB Total and Single-item Scores From Six Randomized, Double-blind, Placebo-controlled Studies. Int J Geriatr Psychiatry. 2009;24(5):532-8. PubMed PMID: 19274640.
    * Article titles in AMA citation format should be in sentence-case
    TY - JOUR T1 - Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies. AU - Mecocci,Patrizia, AU - Bladström,Anna, AU - Stender,Karina, PY - 2009/3/11/entrez PY - 2009/3/11/pubmed PY - 2010/5/27/medline SP - 532 EP - 8 JF - International journal of geriatric psychiatry JO - Int J Geriatr Psychiatry VL - 24 IS - 5 N2 - OBJECTIVES: The post-hoc analyses reported here evaluate the specific effects of memantine treatment on ADAS-cog single-items or SIB subscales for patients with moderate to severe AD. METHODS: Data from six multicentre, randomised, placebo-controlled, parallel-group, double-blind, 6-month studies were used as the basis for these post-hoc analyses. All patients with a Mini-Mental State Examination (MMSE) score of less than 20 were included. Analyses of patients with moderate AD (MMSE: 10-19), evaluated with the Alzheimer's disease Assessment Scale (ADAS-cog) and analyses of patients with moderate to severe AD (MMSE: 3-14), evaluated using the Severe Impairment Battery (SIB), were performed separately. RESULTS: The mean change from baseline showed a significant benefit of memantine treatment on both the ADAS-cog (p < 0.01) and the SIB (p < 0.001) total score at study end. The ADAS-cog single-item analyses showed significant benefits of memantine treatment, compared to placebo, for mean change from baseline for commands (p < 0.001), ideational praxis (p < 0.05), orientation (p < 0.01), comprehension (p < 0.05), and remembering test instructions (p < 0.05) for observed cases (OC). The SIB subscale analyses showed significant benefits of memantine, compared to placebo, for mean change from baseline for language (p < 0.05), memory (p < 0.05), orientation (p < 0.01), praxis (p < 0.001), and visuospatial ability (p < 0.01) for OC. CONCLUSION: Memantine shows significant benefits on overall cognitive abilities as well as on specific key cognitive domains for patients with moderate to severe AD. SN - 1099-1166 UR - https://www.unboundmedicine.com/medline/citation/19274640/Effects_of_memantine_on_cognition_in_patients_with_moderate_to_severe_Alzheimer's_disease:_post_hoc_analyses_of_ADAS_cog_and_SIB_total_and_single_item_scores_from_six_randomized_double_blind_placebo_controlled_studies_ L2 - https://doi.org/10.1002/gps.2226 DB - PRIME DP - Unbound Medicine ER -